German NPWT Consensus Backs 7-Day PICO7 Therapy, Aims to Slash Surgical Costs

For biopharma and medtech investors, clinical guidelines are often the first green shoots of market adoption. The new German consensus on sNPWT, which highlights Smith & Nephew's PICO7 as a preferred system, provides a compelling reimbursement narrative. By targeting postoperative complications — a multi-billion-euro cost burden — the guideline could accelerate uptake of this 7-day, portable therapy, opening a new chapter in value-based surgical care.

The German surgical community has released new consensus-based guidance that could reshape the standard of care for postoperative wound management while addressing a mounting economic burden on healthcare systems. Published in the journal Die Chirurgie, the expert panel’s recommendations advocate for the prophylactic use of single-use negative pressure wound therapy (sNPWT) on closed surgical incisions, underscoring its ability to reduce surgical site complications and associated costs. Supported by global medical technology company Smith & Nephew (NYSE: SNN) — the manufacturer of the PICO7 sNPWT system — the consensus brings Germany’s clinical practice in line with a growing body of international evidence favoring the technology’s clinical and economic value.

“

The company’s Advanced Wound Management segment, which includes PICO, has been a growth engine, with the global NPWT market projected to reach $3.5 billion by 2028.

Postoperative wound complications, including surgical site infections (SSIs) and wound dehiscence, are a persistent and costly problem. In Germany, where hospital reimbursement is governed by the diagnosis-related group (DRG) system, the extra costs of managing such complications are frequently not fully covered, placing significant financial strain on providers. The consensus panel explicitly identifies these complications as a ‘significant and systematic cost driver,’ and points out that the lack of consistent reimbursement creates a perverse incentive that may deter proactive prevention strategies. By issuing formal guidance, the panel aims to standardize care pathways that integrate sNPWT from the operating room through to outpatient recovery, thereby improving both clinical outcomes and resource utilization.

Central to the panel’s practical recommendations is the use of Smith & Nephew’s PICO7, a canister-free, portable sNPWT system that delivers -80 mmHg of negative pressure for up to seven days. Its design features — including a dressing change indicator, leak detection, and battery status alerts — are explicitly noted in the consensus for their ability to support seamless integration into existing care pathways across inpatient and outpatient settings. This is a critical differentiator in a healthcare environment that increasingly emphasizes early discharge and outpatient management. By enabling patients to continue therapy at home, PICO7 can help hospitals avoid prolonged stays, which is the primary driver of complication-related costs.

The economic argument for sNPWT is compelling. Prophylactic NPWT has been shown in multiple randomized controlled trials and meta-analyses to reduce SSI rates by up to 50% and shorten length of stay by an average of two to three days. While the current consensus does not cite a specific percentage reduction, it aligns with the broader clinical evidence base. For a typical German hospital, a two-day reduction in length of stay for high-risk surgical patients can translate to thousands of euros saved per case, especially in cardiac, orthopedic, and abdominal surgeries where SSIs are most prevalent. Given that Germany performs approximately 17 million inpatient surgeries annually, even modest adoption of sNPWT could yield hundreds of millions in annual savings for the health system.

For Smith & Nephew, this consensus is more than a clinical endorsement; it is a strategic market development tool. The company’s Advanced Wound Management segment, which includes PICO, has been a growth engine, with the global NPWT market projected to reach $3.5 billion by 2028. Yet adoption has been uneven, often hindered by a lack of clear, locally relevant reimbursement frameworks. This German-focused guideline addresses that gap directly. It could influence purchasing decisions by hospital procurement committees and statutory health insurers, particularly if it is used to support negotiations for DRG carve-outs or supplementary payments for sNPWT. Moreover, with Germany being the EU’s largest healthcare market, success here can set a precedent for other European countries.